Renal and Vascular Effects of Selective FGFR4 Inhibition in Folic Acid-induced Kidney Injury in Rats
5 affiliations
- 1Department of Pharmacology, University of Health Sciences, Gülhane Faculty of Pharmacy, Ankara, Türkiye
- 2Department of Biochemistry, University of Health Sciences, Gülhane Faculty of Pharmacy, Ankara, Türkiye
- 3Department of Pathology, University of Health Sciences, Gülhane Vocational School of Health, Ankara, Türkiye
- 4Department of Histology and Embryology, University of Health Sciences, Gülhane Faculty of Medicine, Ankara, Türkiye
- 5Gülhane Institute of Health Sciences, University of Health Sciences, Ankara, Türkiye
Abstract
Background/Aim: Fibroblast growth factor-23 (FGF-23) has been implicated in chronic kidney disease (CKD)-associated cardiovascular dysfunction, potentially through fibroblast growth factor receptor 4 (FGFR4). This study investigated renal and vascular alterations in folic acid-induced CKD and evaluated the effects of selective FGFR4 inhibition.
Materials and Methods: Male Sprague-Dawley rats were assigned to healthy control, CKD control, vehicle, and roblitinib-treated groups. CKD was induced by a single intraperitoneal dose of folic acid. Serum creatinine, FGF-23, tumor necrosis factor-α, interleukin-1β, and asymmetric dimethylarginine levels were measured. Vascular reactivity was evaluated in isolated aortic rings using phenylephrine, carbachol, and sodium nitroprusside. Renal fibrosis, carotid calcification, and medial thickness were assessed histologically.
Results: Folic acid administration increased serum creatinine and relative kidney weight and impaired both endothelium-dependent and endothelium-independent vascular relaxation. Relative kidney weight was lower in the roblitinib-treated group than in the CKD control group. However, changes in vascular responses observed in both the treatment and vehicle groups prevented these effects from being attributed specifically to FGFR4 inhibition. FGF-23 and inflammatory marker levels did not differ significantly among the groups. Carotid medial thickness was significantly greater in the treatment group than in the CKD-control group (p<0.05), whereas no other significant between-group differences were detected.
Conclusion: Folic acid-induced renal injury was associated with early functional vascular impairment despite limited structural and inflammatory alterations. Selective FGFR4 inhibition did not demonstrate a clear therapeutic effect. Further invivo studies using complementary CKD models, direct assessment of FGFR4 signaling, and vehicle formulations without intrinsic vascular activity are required to validate these findings.
Related
- BD2-selective BRD4 inhibitor ZX29 mitigates myocardial ischemia-reperfusion injury via BRD4-YY1-NCOA4 axis disruption and ferroptosis inhibition.
- TNFSF14 deficiency attenuates the ischemia/reperfusion-induced acute kidney injury-to-chronic kidney disease transition by upregulating PGC-1α expression
- Differential Protection against Acetaminophen-induced Liver and Kidney Injury by N-Acetylcysteine and Fomepizole in Female Mice
- Modified 3rd Generation Synchronization Modulation Electric Field (3m-SMEF) Prevents Ischemia-Reperfusion-Induced Acute Kidney Injury via Targeting Na⁺/K⁺-ATPase
- Empagliflozin attenuates traumatic brain injury-induced atherosclerosis and norepinephrine-induced vascular smooth muscle cell responses
BibTeX
@article{rumanli2026renal,
title = {{Renal and Vascular Effects of Selective FGFR4 Inhibition in Folic Acid-induced Kidney Injury in Rats}},
author = {ZELIHA RUMANLI and EMRE AVCI and ÜLKÜ İREM YILMAZ and BARIŞ BAYKAL and BEYHAN KARLI YILDIRIM and OKAN ALI AKSOY and BERK ALP GÖKSEL and İSMAIL MERT VURAL},
journal = {In Vivo},
year = {2026},
month = oct,
doi = {10.21873/invivo.14498},
url = {https://doi.org/10.21873/invivo.14498},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Renal and Vascular Effects of Selective FGFR4 Inhibition in Folic Acid-induced Kidney Injury in Rats
AU - ZELIHA RUMANLI
AU - EMRE AVCI
AU - ÜLKÜ İREM YILMAZ
AU - BARIŞ BAYKAL
AU - BEYHAN KARLI YILDIRIM
AU - OKAN ALI AKSOY
AU - BERK ALP GÖKSEL
AU - İSMAIL MERT VURAL
PY - 2026
DA - 2026/10/29
JO - In Vivo
DO - 10.21873/invivo.14498
UR - https://doi.org/10.21873/invivo.14498
AB - Background/Aim: Fibroblast growth factor-23 (FGF-23) has been implicated in chronic kidney disease (CKD)-associated cardiovascular dysfunction, potentially through fibroblast growth factor receptor 4 (FGFR4). This study investigated renal and vascular alterations in folic acid-induced CKD and evaluated the effects of selective FGFR4 inhibition. Materials and Methods: Male Sprague-Dawley rats were assigned to healthy control, CKD control, vehicle, and roblitinib-treated groups. CKD was induced by a single intraperitoneal dose of folic acid. Serum creatinine, FGF-23, tumor necrosis factor-α, interleukin-1β, and asymmetric dimethylarginine levels were measured. Vascular reactivity was evaluated in isolated aortic rings using phenylephrine, carbachol, and sodium nitroprusside. Renal fibrosis, carotid calcification, and medial thickness were assessed histologically. Results: Folic acid administration increased serum creatinine and relative kidney weight and impaired both endothelium-dependent and endothelium-independent vascular relaxation. Relative kidney weight was lower in the roblitinib-treated group than in the CKD control group. However, changes in vascular responses observed in both the treatment and vehicle groups prevented these effects from being attributed specifically to FGFR4 inhibition. FGF-23 and inflammatory marker levels did not differ significantly among the groups. Carotid medial thickness was significantly greater in the treatment group than in the CKD-control group (p<0.05), whereas no other significant between-group differences were detected. Conclusion: Folic acid-induced renal injury was associated with early functional vascular impairment despite limited structural and inflammatory alterations. Selective FGFR4 inhibition did not demonstrate a clear therapeutic effect. Further invivo studies using complementary CKD models, direct assessment of FGFR4 signaling, and vehicle formulations without intrinsic vascular activity are required to validate these findings.
SN - 0258-851X
SN - 1791-7549
ER -